ARCHIVES

FDA Approves Gemzar For Ovarian Cancer, Contradicting ODAC Recommendation; Continues Agency Trend to Recognize Progression-Free Survival As An Endpoint.

This article is from The Cancer Letter archive.

Vol. 32 No. 28 | July 21, 2006

Download PDF Visit The Full Archive

Related Articles

High-Priority Radiation Therapy Research Projects Approved By DCT Board of Counselors

March 26, 1976

In Brief: Ozer, Comis Join Allegheny Cancer Centers; Two Cooperative Groups Under Same Roof

March 21, 1997

Research Opportunities Growing, $$ Shrinking, Young Tells Congress

March 29, 1991

USDA Expands Role In 5 A Day Partnership

April 26, 2002

Market Forces Changing Health Care System, Oncologists Told

June 2, 1995

In Brief: Stipends Out For Trainees In new Clinical Program, But They Can Be Paid If Any Money Is Available

May 31, 1974